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Assessment of long-term neurodevelopmental outcome
following trials of medicinal products in newborn infants
Neil Marlow1, Lex W. Doyle2, Peter Anderson3, Samantha Johnson4, Varsha Bhatt-Mehta5, Giancarlo Natalucci6, Brian A. Darlow7,
Jonathan M. Davis8 and Mark A. Turner9 for the International Neonatal Consortium (INC)
There is signiﬁcant uncertainty over the role of assessment of long-term neurodevelopmental outcome (LTO) in neonatal clinical
trials. A multidisciplinary working group was established to identify key issues in this area and to make recommendations about
optimal approaches to evaluate LTO in therapeutic trials in newborns, which can be developed by sponsors and investigators with
other key stakeholders. A key consideration for neonatal trials is the potential for the investigational product to cause widespread
effects and drives the need to assess outcome in multiple organs. Thus investigators must assess whether the product has an
impact on the brain and the potential for it to cause potential effects on LTO. Critically, is assessment of LTO an important direct
therapeutic target or a safety outcome? Such decisions and outcomes need to be speciﬁc to the product being studied and use
published data, only considering expert opinion when prior evidence does not exist. In designing the trial, the balance of beneﬁts,
costs, and burdens of assessments to the researcher and families need to be considered. Families and parent advocates should be
involved in design and execution of the study. A framework is presented for use by all key stakeholders to determine the need,
nature, and duration of LTO assessments in regulatory trials involving newborn infants.
Pediatric Research (2019) 86:567–572; https://doi.org/10.1038/s41390-019-0526-1
INTRODUCTION
The effect of an investigational medicinal product (IMP) or other
interventions administered to newborn infants may be detected
well beyond the neonatal period. The extent of the affected
domains has been set out in a report of a workshop held in 2011.1
Recent advances in neuroprotection following intrapartum
hypoxia at term have highlighted the complexity of long-term
neurodevelopmental outcome (LTO) from hypoxic–ischemic
encephalopathy (HIE).2,3
The study of most pharmacologic and non-pharmacologic
interventions in the newborn infant will require monitoring of
outcomes beyond discharge from inpatient neonatal services.
This is needed to detect the primary outcome, to conﬁrm
persistence of neonatal effects of the intervention, or to
demonstrate long-term safety.4 Rapid and continued develop-
ment as well as the non-speciﬁcity of medicines used in the
neonatal period means that investigational products rarely have
precisely targeted effects. Products given in the neonatal period
may subtly alter the developmental trajectory of organ
development, for example, lung or vascular development,5 such
that the effects are only detectable as the organ system
matures. This phenomenon is compounded by the effects of
factors other than the study intervention on development and
maturation as well as a lack of reliable early biomarkers of
effectiveness or adverse effects for most conditions that appear
in children after neonatal illness.
This narrative review considers factors associated with neonatal
LTOs while drawing attention to other domains when appropriate.
It reﬂects the views of a broad spectrum of individuals from
clinical practice, industry partners, and regulators.
NEONATAL LONG-TERM OUTCOME STUDIES
In general, long-term follow-up is often conducted in studies that
are separate yet coordinated with the initial clinical trials. Long-
term studies are not easy to do as they require tracking of children
and their families after discharge from hospital for several years or
more, which can be expensive and overly burdensome.6 Trials of
investigational products in newborn infants may need to include
suitable tracking and retention strategies as part of the licensing
process, unless it can be linked to routine LTO follow-up that is
part of the standard care. Dropouts in long-term outcome studies
are common in both academic and industry-based studies—and
they are rarely at random, preferentially affecting children with
adverse outcomes7,8 and those from socially disadvantaged
backgrounds.9,10 Trial size calculations for long-term studies (e.g.,
within post-approval registries) need to account for a realistic
proportion of dropouts in order to ensure adequate data quality.
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Certain effects may not be detectable for many years. For
example, lung function tests are not reliable until later in
childhood11; executive functions, the building blocks of cognitive
function in childhood and adult life, differentiate into separable
functions that are more reliably assessed at school age12; changes
in vascularization affecting blood pressure may not reliably be
detected until early adolescence.13 While important outcomes
may not manifest until 5–10 years after exposure, it is not practical
to wait this long for licensing/marketing authorization.
These considerations mean that it is important to determine
which LTOs are central to licensing and which will inform post-
marketing assessments. Direct evidence of clinical beneﬁt is
usually required for licensing, unless a validated surrogate
endpoint can be identiﬁed. Many assessments currently con-
ducted during the neonatal period are not speciﬁc or sensitive
predictors of important clinical outcomes, either as beneﬁt or
harm, and so are unlikely to provide validated surrogate
endpoints.
Delays and difﬁculties often arise during long-term outcome
studies. If long-term studies are unnecessarily included in the
initial assessment for licensing or marketing authorization,
there may be delays in approval that prevent infants from
accessing a useful product. Delays can also lead to reduced
feasibility because off-label drug use removes equipoise and
because delays can cause investigator and parent fatigue.
However, longer-term assessments may be essential to estab-
lish both safety and efﬁcacy of some investigational products.
The decision about which outcomes to use as the basis for
neonatal licensing should be made early during the process to
approve the pediatric development plan or its constituent studies.
The role and nature of shorter-term outcomes will depend on the
natural history of the condition, the known and expected
properties of the product, and the speciﬁc neonatal population
that is investigated. The licensed indication may not be the same
as the clinical diagnosis. Outcomes need to be relevant to families
and clinicians (and other stakeholders such as reimbursement
agencies). The sponsor should present a well-reasoned proposal
for which outcomes should contribute to licensing with a speciﬁc
focus on outcomes that should be included in Pharmacovigilance
Risk Management Plans or adaptive licensing. Short-term risks and
beneﬁts may not be concordant with long-term outcomes. For
example, cranial ultrasound may not detect abnormalities in
infants who subsequently develop cerebral palsy, neurocognitive,
or behavioral problems. However, potential discordance is a
justiﬁcation for well-designed surveillance that makes account of
this possibility, not for delaying licensing once evidence of a useful
clinical effect is apparent. A transient beneﬁt seen over 1–2 years
that is not reﬂected in later life may still be valued by families and
payers.
Understanding the multiple inﬂuences that are active during
childhood is equally important, as these may confound the
results of clinical trials. For example, males have worse outcomes
than females in many neonatal studies. Family structure may
inﬂuence how a child acquires skills, as may the language
spoken at home (if more than one), particularly when testing
is done as structured language is appearing in the second
and third years of life. Finally, the socio-economic status of the
family and availability of interventional services may modify
both short- and long-term outcomes. Data collection should
capture these inﬂuences as it is necessary to include sensitivity
analyses as secondary exploratory analyses. In large multicenter,
randomized, controlled trials, sample size and randomization
should be robust enough to ensure even allocation of
confounders between the study groups. However, randomiza-
tion does not necessarily inﬂuence the balance of confounders
that may arise subsequently (e.g., meningitis occurring in
infancy or new onset of seizure disorders; both may affect
neurodevelopment).
FRAMEWORK FOR PLANNING LTO EVALUATIONS
This section presents general points to be considered when
assessing the need for, and structure of, LTO evaluations for
neonatal trials. Points to consider may include:
1. Justify all trial design components according to the speciﬁc
trial drug—This will include the investigational product
itself, the indication for use of the product, and the
population where it will be tested. Other interventions,
such as the use of therapeutic hypothermia during HIE,
should be reﬂected in the justiﬁcation. All components
should be justiﬁed using data, reverting to expert profes-
sional opinion only when necessary.
2. Account for the nature of the outcome as a primary target or
safety consideration—where the outcome is a direct
consequence of the intervention, a formal evaluation of a
deﬁned LTO is necessary, tailored to detect the proposed
effect (Fig. 1a). Where the investigational product may be
associated with adverse LTO, this may not necessarily be a
direct consequence of the treatment effect but other causal
pathways. In this instance, it is safer to evaluate all outcome
domains (Fig. 1b). There is a co-dependency of adverse
outcome domains primarily because many causal pathways
are common. The pathogenesis of poor neurodevelopmen-
tal outcomes is complex and many prenatal and postnatal
inﬂuences combine with the child’s environment to produce
a particular outcome. These inﬂuences will usually be evenly
segregated between trial groups through the randomization
process. In some trials, it may be appropriate to ensure even
recruitment through stratiﬁcation or minimization techni-
ques to account for the confounding inﬂuences that are
identiﬁable at study entry. Examples of important confoun-
ders for LTO are male sex, gestational age, fetal growth,
neonatal brain injury, and socio-economic status.14–16 Trial
data should include all of these potential confounders.
3. Balance the beneﬁts, costs, and burden of the assessments—
these may be balanced against the assessments themselves,
the intervention, the indication, and the population (includ-
ing co-morbidities).
With respect to each time that contact is made with a
family, it is important to consider:
a. The burden on the participant and family
b. The burden on the health-care system both during the
trial and subsequently if the role of the intervention
changes after the trial (i.e., use becomes more general-
ized)
c. Costs to the family (direct and indirect) against utility for
the sponsor. With respect to the intervention, consider:
d. Beneﬁts against risk
i. Anticipated
ii. Potentially unanticipated
iii. The magnitude of the beneﬁt or risk
With respect to the population, consider:
e. What are the inherent risks in the population (the impact
of the initial disease process on LTO) that the investiga-
tional product seeks to mitigate?
The direct costs and resources required for long-term follow-up
should be identiﬁed and guaranteed before the trial starts. Sponsors,
clinicians, academics, and relevant advocacy groups should all
facilitate long-term follow-up by designing the studies carefully and
by contributing to/advertising the studies when appropriate. Health-
care systems should provide support to long-term follow-up studies
by providing suitable infrastructure that promotes long-term follow-
up—which in any case is essential for the responsible clinical care of
newborn infants (especially preterm infants) and by maintaining
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systems that provide unique identiﬁers. The collection of high-
quality data in routine clinical practice may also contribute to LTO
assessments but requires standardization and coordination across
multiple settings that may not be feasible.
4. Involve families and parent advocates in the study design—
this should be proportional to the design and involvement of
the trial and likely beneﬁt. As a general principle, the input of
families will assist in ensuring that the trial is relevant,
acceptable, and feasible to service users. It is acknowledged
that sometimes such input may lead to alteration of
commonly used assessments: e.g., speciﬁc parental questions
or instruments. For example, parents may request that certain
questions be removed from standard questionnaires because
they appear to be insensitive in current usage, which may
change the overall psychometric properties of the instrument.
However, the input of families is often of great beneﬁt in
ensuring that the risk/beneﬁts/burden of the trial is optimized.
Where such input is sought, resources need to be made
available to participants to facilitate their input, including
reimbursement for their time and travel.
5. Account for the nature of the intervention—in terms of likely
effects and use:
a. What is known about drug disposition in the target group
(absorption, distribution, metabolism, excretion, toxicity,
integrity of the blood–brain barrier)?
b. What is known of toxicology in appropriate preclinical
models?
c. Are there likely effects from excipients or formulation
strategies?
d. How is the drug to be administered?
e. What is known about the neurological impact in terms of
beneﬁts or harms, the likelihood of these impacts, and the
extent to which these can be excluded as issues?
6. Account for the background morbidity in the population—
medicines rarely remove all morbidity in clinical populations
as most morbidities have complex and multifactorial
etiologies. In any population, there will be background
morbidities which may confound the effects that are being
studied. Thus, particularly when attempting to evaluate the
effects of drugs on LTO, the population baseline outcomes
must be known and will differ—some examples of
populations with very differing risks may be:
a. Term infants with suspected infection
b. Term infants recruited to vaccine studies
c. Term infants with HIE
d. Preterm infants ≤32 weeks postmenstrual age with an
oxygen requirement
e. Preterm infants ≤26 weeks with poor perfusion and/or
hypotension
7. Account for the nature of the trial—several types of
investigation are relevant to these considerations, including
regulated submission for marketing authorization/labeling,
contribution to prescribing (strategic trials), and to health
technology assessment. Data from trials may be relevant to
other trial situations and data should be re-used for other
relevant purposes if at all possible, to minimize the “ask” of
families. Furthermore, the studies and data required to
obtain marketing authorization may not be suitable to
change clinical practice or justify reimbursement, and the
sponsor may feel it is necessary to add assessments beyond
these minimal requirements. However, each additional
assessment must be thoroughly justiﬁed.
8. The plan for LTO evaluation—Following consideration of the
above issues, a bespoke plan can be made or one or more of
the following plans may be followed:
a. No speciﬁc long-term follow-up is necessary beyond the
initial hospital discharge
b. Studies should retain a unique identiﬁer to allow record
linkage with routine health data
c. Studies should retain contact with the family and ask
general questions about their health status
d. Studies should screen participants for important LTO:
assessments should be established a priori and any
positive screens evaluated if/when they occur
e. There should be formal follow-up of all participants at
appropriate time intervals to directly evaluate their
clinical and neurodevelopmental status
f. Follow-up should be conducted using a registry (new or
existing) that includes participants in studies recruiting
during pregnancy or the neonatal period. This could
include other infants exposed to the IMP.
The plan will be different depending on the feasibility of
ongoing surveillance, the relative prevalence of anticipated
outcomes in different populations, and on the likelihood of brain
or other organs having adverse outcomes.
TECHNICAL ISSUES IN PLANNING EVALUATION OF LTOS
The online Supplemental Material describes the considerations
and details of speciﬁc neurodevelopmental assessments, drawn
Other neonatal
pathway(s)
Environment
/rearing
2y OUTCOME 2y OUTCOMEIMPIMP
Other neonatal
pathway(s)
Indirect
neonatal effect
Direct
neonatal effect
Direct
neonatal effect
e.g. Magnesium sulphate
       Melatonin
       Developmental intervention
e.g. Indomethacin: via lower PDA, IVH, other
       Caffeine: via lower BPD, diuretic effect, other
       Respiratory intervention: via lower BPD, other
Environment
/rearing
Fig. 1 Causal pathways to adverse long-term outcomes and needs for assessment. a Where the outcome is a direct consequence of the
intervention, a formal evaluation of a deﬁned long-term neurodevelopmental outcome (LTO) is necessary, tailored to detect the proposed
effect. b Where the outcome is an indirect consequence of the intervention, it is safer to evaluate all domains of relevant LTOs
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from professional consensus and previous studies, with explana-
tory notes on the reasons for choice of measure, and categoriza-
tion of outcomes for safety purposes. These categories are used
worldwide as outcomes for a range of clinical and medicine-
related studies and are especially relevant in neonatal trials. If an
investigational product is to achieve clinical acceptability, the
quality and nature of the outcome assessment should be
understood by the entire clinical community with reference to
common practice. That is not to say that innovative outcomes are
not of value, but that they must be set in context and be of
sufﬁcient validity, reliability, and quality to have conﬁdence in
clinical applicability. Further, speciﬁc products may need tailored
outcomes depending on the target and the nature of the organ
effect that is being studied.
With respect to neurodevelopmental outcomes, trials may be
grouped as those where the investigational product is targeting
speciﬁc neurological outcomes or where general safety monitor-
ing is required, which could include neurodevelopmental
outcome. Although speciﬁc recommendations of assessment
methods are made (in an attempt to standardize and harmonize
approaches), these examples are not intended to preclude the use
of other instruments or assessment tools.
AGES AT ASSESSMENT
Because of the lack of robust biomarkers for LTOs, which are
needed, it is necessary to evaluate trial participants up to an age at
which the evaluation identiﬁes reliable indicators of long-term
outcomes. For efﬁcacy of neurologically focused interventions or
for assessment of neurological safety, the primary outcome should
be evaluated at 2 years of age (corrected for prematurity if
appropriate), as the focus of the ﬁrst phase of LTO monitoring.
Such an assessment is performed by many neonatal teams for
audit and quality-control purposes in high-risk cohorts and may
be adapted during data collection for trials. The rationale and
recommended classiﬁcations have been published (Fig. 2) and the
Motor
Cognitive function
No useful hearing even with aids
(profound > 90 dBHL)
Blind
or
can only perceive light or
light reflecting objects
No meaningful words/signs
or
unable to comprehend cued command
(ie, commands only understood in a familiar
situation or with visual cues eg, gestures)
Score <–3SDs below norm (DQ < 55) Score –2SD to –3SD below norm (DQ 55–70)
Hearing loss corrected with aids
(usually moderate 40–70 dBHL)
or
Some hearing but loss not corrected by aids
(usually severe 70–90 dBHL)
Some but fewer than 5 words or signs
or
unable to comprehend uncued command
but able to comprehend a cued command
Seems to have moderately reduced vision but
better than severe visual impairment;
or
blind in one eye with good vision in the
contralateral eye
Cerebral palsy with GMFCS level 3, 4 or 5 Cerebral palsy with GMFCS level 2
Hearing
Speech & language
Vision
Respiratory
Renal Requires dialysis or awaiting organ transplant
GMFCS; Gross Motor Function Classification System; SD, Standard Deviation; DQ, Developmental Quotient
Requires parenteral nutrition,
gavage or gastrostomy feeding
Requires continued respiratory support
or oxygen
Severe impairment Moderate impairment
Gastrointestinal
Domain Any one of the following:
Severe neurodevelopmental impairment
Other disabilities (included as additional impairments to severe or moderate neurodevelopmental disability)
Criteria for Moderate neurodevelopmental impairment
Any one of the following:
Renal impairment requiring treatment
or special diet
On special diet or has stoma
Limited exercise tolerance
Fig. 2 Example of a consensus scheme for categorization of health status at 2 years of age, including neurodevelopmental outcomes17
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assessments are discussed in greater detail in the web supple-
ment. These should be supplemented with treatment-speciﬁc
outcomes as appropriate (e.g., seizure frequency in the study of an
anti-epileptic medication). These outcomes may be considered
necessary to support licensing where the effects of the investiga-
tional product are not directly quantiﬁable during the neonatal
period.
To rely completely on 2-year (or even earlier) outcomes runs the
risk of misclassiﬁcation of ﬁnal outcome and of missing more
subtle cognitive, behavioral, or sensorimotor outcomes. Assess-
ments performed at 2 years corrected gestational age are
performed when many pathological outcomes are still differen-
tiating as part of the normal child development (Fig. 2). Accurate
ascertainment of neurocognitive, academic, and behavioral
assessments requires children to be followed until later in
childhood when school performance can be better assessed. All
of these conditions are more accurately measured at later ages
and tend to differentiate during the ﬁrst 4–6 years after birth.
From early school age, cognitive scores tend to track in individuals
and more precise deﬁnition of motor and sensory outcomes is
possible. Where appropriate, these assessments should be
combined with treatment-speciﬁc measures to enhance the
understanding of the very long-term effects of the product. While
outcomes at 5–6 years of age are important conﬁrmatory
assessments, generally they should supplement licensing pro-
cesses and are not necessarily required for initial licensing because
of the lag time to their detection.
In some settings, it may be prudent to collect routine data
from national systems to support safety and very long-term
outcomes—examples of this may be ongoing mortality or
cancer registration monitoring or the results of standardized
national educational attainment tests. As most studies are
carried out in international settings, care needs to be taken
when proposing to use such assessments as these may not be
an adequate substitute for research-speciﬁc assessments and
highlights difﬁculties in comparing outcomes between different
health-care and education systems. This may be due to
inconsistencies in granularity or data quality or in the scope of
geographic coverage relative to trial recruitment. Nevertheless,
these are potentially important surveillance tools and may
identify important long-term risks when appropriate. In addition
to these assessments, it may be prudent to add additional
focused assessment to support licensing of particular products.
All ongoing data collection should meet relevant national data
protection regulations, which should be factored into trial
planning and delivery.
POST-DISCHARGE DEATHS
At each assessment point, the number of patients who have
died and the principal reason for death should be recorded,
together with any pre-existing identiﬁed disabilities. Deaths may
confound some trials and any assessment plans should indicate
how deaths are to be treated in the analysis, even if the product is
not thought to directly relate to the death. Since death is often a
competing outcome, it is not uncommon to see combined
primary outcome measures, which include death or another
serious morbidity.
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(e.g. Prechtl at 40w & 52w PMA)
Hearing screening
ROP screening if indicated
Obtain parental permission for links to health
data and school progress as appropriate
Structured neuro examination
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Formal quantitative developmental test
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Behavior
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Standardized examination
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Parental assessment (PARCA-r)
Categorize impairment
Resource utilization
Specific symtoms (e.g. seizures/ISAAC)
Behavior
Standardised examination
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School report
General cognitive test
Neuromotor skills evaluation
Categorise impairment
Key executive functions
Adaptive functioning
Behavioural assessment
Resource utilisation
Other specific outcomes
School attainment
(mortality/cancer monitoring)
Other specific assessments as indicated
e.g. MRI scan
School attainment
(mortality/cancer monitoring)
Discuss on individual application basis
Term equivalent/
early infancy
(to 12 months of age)
Neurologically focused IMP Age range Safety assessment
24 months
5–6 years
Longer term
Fig. 3 Summary of proposals for long-term neurodevelopmental outcome assessment strategy
Assessment of long-term neurodevelopmental outcome following trials of. . .
N Marlow et al.
571
Pediatric Research (2019) 86:567 – 572
CONCLUSION
Clinical trials of IMPs in the neonatal period may require long-term
evaluations for assessment of both therapeutic and safety
signals. Drugs may have negative effects on the infant, both
directly and unanticipated, which may be detected early in
the neonatal period or later at school age. This paper conceptua-
lizes recommendations for the examination of long-term out-
comes and proposes a framework within which more speciﬁc
outcomes pertinent to the investigational product may be
added (Fig. 3).
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